A phase 1 trial suggests that the multipeptide T-cell activator iTAC-XS15-CLL could be a safe and promising immunotherapy for patients with chronic lymphocytic leukemia receiving BTK inhibitors. The study enrolled 20 patients with minimal residual disease who were in partial remission after treatment with ibrutinib, acalabrutinib, or zanubrutinib. Each patient received three doses of a […]
A new study is reshaping understanding of pancreatic ductal adenocarcinoma (PDAC), showing that PI3K signaling—key to tumor growth—can persist without direct activation by mutant KRAS. Researchers found that a common mutation, KRAS G12R, cannot activate PI3K, yet tumors still maintain strong pathway activity, suggesting an alternative mechanism is at work. The study points to the
PI3K Signaling in Pancreatic Cancer Can Bypass KRAS Through PTEN Oxidation Read More »
A new study highlights the Netrin-1 (NTN1) and Neogenin-1 (NEO1) signaling pathway as a major driver of pancreatic ductal adenocarcinoma (PDAC). Researchers found both proteins are highly overexpressed in tumors, fueled by KRAS mutations and stress signals from nearby nerves. These pathways create a self-reinforcing loop that supports tumor growth and spread. The research shows
Netrin-1 Pathway Found to Drive Tumor Growth and Nerve Expansion in Pancreatic Cancer Read More »
Researchers are shifting how they treat pancreatic ductal adenocarcinoma (PDAC), focusing on the KRAS mutation that drives more than 90% of cases. This mutation locks KRAS in an “on” state, causing continuous cancer cell growth and making the disease resistant to many standard treatments, including immunotherapy. New findings show KRAS also shapes the tumor’s immune
KRAS-Targeted Therapies Signal New Direction in Pancreatic Cancer Treatment Read More »
Partner Therapeutics has submitted a supplemental application to the U.S. Food and Drug Administration seeking approval of zenocutuzumab-zbco for adults with advanced or metastatic cholangiocarcinoma carrying NRG1 gene fusions. The National Comprehensive Cancer Network has already added the drug to its guidelines as a recommended option in biliary tract cancers. The submission is supported by
FDA Review Sought for zenocutuzumab-zbco in NRG1 Fusion–Positive Bile Duct Cancer Read More »
The OptimUM-02 trial shows that the oral combination of darovasertib and crizotinib significantly improves outcomes for patients with a difficult-to-treat form of eye cancer, metastatic uveal melanoma that is HLA-A*02:01–negative. The treatment doubled median progression-free survival to 6.9 months compared to 3.1 months with standard therapies. It also reduced the risk of disease progression or
Oral Darovasertib–Crizotinib Combo Shows Strong Results in Hard-to-Treat Eye Cancer Read More »
Mevrometostat, an experimental EZH2 inhibitor, is showing strong potential for treating metastatic castration-resistant prostate cancer by blocking “lineage plasticity,” a process that allows cancer cells to change and resist hormone therapy. When combined with enzalutamide, the treatment significantly improved outcomes in early studies. In a phase 1 trial, the combination nearly doubled median radiographic progression-free
Mevrometostat Combo Therapy Shows Strong Early Results in Advanced Prostate Cancer Read More »
Researchers have developed an experimental nanotherapy aimed at overcoming two major challenges in treating glioblastoma: the blood-brain barrier and drug resistance. The approach uses tiny lipid particles called liposomes to carry two existing drugs—everolimus (or rapamycin) and vinorelbine—directly to tumor cells. By delivering both drugs together, the therapy blocks tumor growth pathways and prevents cancer
Researcher Develops Nanotherapy to Break Barriers in Glioblastoma Treatment Read More »
The Phase 3 TANGENT trial showed that emactuzumab significantly improves outcomes for patients with tenosynovial giant cell tumor compared to placebo. At six months, patients receiving the drug had higher tumor response rates and greater reductions in tumor size. Many also experienced quick and lasting improvements in physical function, including less pain, better movement, and
Interim results from the phase 2 ALPHA3 trial suggest that cema-cel, an off-the-shelf CAR T-cell therapy, may significantly improve outcomes for patients with large B-cell lymphoma who remain MRD-positive after initial treatment. In this high-risk group, the therapy achieved MRD negativity in 58.3% of patients, compared to just 16.7% with standard observation. Circulating tumor DNA
Off-the-Shelf CAR T Therapy Cema-Cel Shows Strong Early Results in Lymphoma Trial Read More »